시장보고서

상품코드

1781937

이중특이성항체 시장 : 약제 유형별, 적응증별, 유통 채널별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Bispecific Antibodies Market, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 06월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

이중특이성항체 시장 규모는 2024년에 109억 9,209만 달러에 달하며, 2025-2032년에 CAGR 40.10%로 확대

이중특이성항체 시장 - 시장 역학

FDA 승인 증가로 시장 수요 증가 촉진

미국 FDA는 2022-2024년 사이에 6개의 이중특이성항체를 승인했으며, 이는 혁신적인 암 치료에 대한 규제 당국의 지원 증가를 반영합니다. 또한 암 부담 증가는 첨단 면역치료에 대한 수요를 가속화하고 있으며, 이특이성 항체와 같은 표적치료제에 대한 투자를 촉진하고 있습니다. 그러나 복잡한 제조 공정과 높은 개발 비용이 이특이성 항체 시장의 성장에 걸림돌이 되고 있습니다. 반대로 암 연구에 대한 정부의 자금 지원은 기술 혁신의 가능성을 넓히고, 세계 이중특이성항체 시장에 큰 성장 기회를 가져다주고 있습니다.

이중특이성항체 시장 - 주요 인사이트

당사의 리서치 애널리스트들의 분석에 따르면 세계 시장은 예측 기간(2025-2032년) 동안 매년 약 40.10%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

약물 유형별 세분화에서는 면역글로불린 G가 2024년 가장 높은 시장 점유율을 보였습니다.

적응증별로는 암이 2024년 주요 적응증으로 나타났습니다.

지역별로는 북미가 2024년에 매출을 창출하는 주요 시장이 될 것으로 예측됩니다.

이중특이성항체 시장 - 세분화 분석

이중특이성항체 세계 시장은 약물 유형, 적응증, 유통 채널, 지역을 기준으로 세분화됩니다.

적응증별로는 염증성 자가면역질환, 암, 기타로 분류됩니다. 예측 기간 중 암 분야가 큰 시장 점유율을 차지할 것으로 예측됩니다. 이는 주로 전 세계 암 부담 증가와 종양세포를 표적으로 하여 면역반응을 활성화하는 이중특이성항체의 임상적 성공에 기인합니다.

이 시장은 유통 채널별로 드럭스토어, 소매 약국, 병원약국, 온라인 약국 등 4가지로 분류됩니다. 병원 약국 부문이 큰 시장 점유율을 차지할 것으로 예측됩니다. 이는 이중특이성항체가 주로 암이나 자가면역질환과 같은 복잡한 병증에 사용되며, 전문적인 투여, 모니터링, 입원 치료가 필요하기 때문입니다.

이중특이성항체 시장 - 지역적 인사이트

북미는 첨단화된 헬스케어 인프라, 활발한 R&D 투자, 미국 FDA와 같은 기관의 조기 승인에 힘입어 예측 기간 중 세계 이특이성 항체 시장에서 주요 시장 점유율을 차지할 것으로 예측됩니다.

한편, 아시아태평양은 암 발병률 증가, 임상검사 활동 활성화, 의료 접근성 확대, 중국, 인도, 한국 등의 국가에서 바이오의약품 투자 증가로 인해 가장 빠른 속도로 성장할 것으로 예측됩니다.

이중특이성항체 시장 - 경쟁 구도

표적 면역치료제에 대한 수요 증가로 경쟁이 치열해지면서 각 업체들은 기술 혁신, 임상 개발, 의약품 승인에 중점을 둔 전략을 취해야 하는 상황에 직면해 있습니다. 각 회사는 이특이성 항체 포맷의 강화, 안전성 프로파일 개선, 암 및 자가면역 치료의 효능 향상을 위해 연구개발에 많은 투자를 하고 있습니다. 전략적 제휴, 라이선싱 계약, 신흥 시장 진출도 주요 접근 방식입니다. 또한 각사는 첨단 플랫폼과 독자적인 기술을 활용하여 파이프라인의 진전을 가속화하고 빠르게 변화하는 치료 환경 속에서 장기적인 경쟁 우위를 확보하기 위해 노력하고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제11장 주요 벤더 분석 - 이중특이성항체 산업

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- Amgen
- Genentech
- Akeso, Inc.
- Taisho Pharmaceutical
- Janssen
- Immunocore
- Adimab, Innovent Biologics, Inc.
- AstraZeneca
- Affimed GmbH
- Xencor
- F. Hoffmann-La Roche Ltd.
- Sanofi
- Regeneron Pharmaceuticals Inc.
- Pieris Pharmaceuticals, Inc.
- Eli Lilly
- Mereo BioPharma Group plc
- Merus
- MacroGenics, Inc.
- Sobi, TG Therapeutics Inc.
- Genmab A/S
- Alteogen
- Emergent BioSolutions Inc.
- Novartis AG
- Astellas Pharma Inc.
- Celgene Corporation
- 기타

제12장 애널리스트의 전방위적 전망

KSA 25.08.08

REPORT HIGHLIGHT

Bispecific antibodies market size was valued at US$ 10,992.09 Million in 2024, expanding at a CAGR of 40.10% from 2025 to 2032.

Bispecific antibodies are engineered proteins designed to recognize and bind to two different antigens simultaneously. Unlike traditional monoclonal antibodies that target a single molecule, bispecific antibodies can engage two targets, such as a cancer cell and a T-cell, enhancing immune response and therapeutic precision. This dual-targeting ability makes them highly effective in treating complex diseases like cancer, autoimmune disorders, and infectious diseases, offering improved outcomes and reduced off-target effects.

Bispecific Antibodies Market- Market Dynamics

Increasing FDA approvals to propel market demand

The growing approval of bispecific therapies is driving market expansion, with the U.S. FDA approving 6 bispecific antibodies between 2022 and 2024, reflecting rising regulatory support for innovative cancer treatments. Besides, increasing cancer burden is accelerating demand for advanced immunotherapies, prompting investment in targeted therapeutics like bispecific antibodies. However, complex manufacturing processes and the high development costs continue to challenge bispecific antibodies market growth. On the contrary, government funding for cancer research is expanding innovation potential, which is providing massive growth opportunities for the global bispecific antibodies market.

Bispecific Antibodies Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 40.10% over the forecast period (2025-2032)

Based on Drug Type segmentation, immunoglobulin G was predicted to show maximum market share in the year 2024

Based on Indication segmentation, cancer was the leading Indication in 2024

On the basis of region, North America was the leading revenue generator in 2024

Bispecific Antibodies Market- Segmentation Analysis:

The Global Bispecific Antibodies Market is segmented on the basis of Drug Type, Indication, Distribution Channel, and Region.

The market is divided into three categories based on Indication: inflammatory & autoimmune disorder, cancer, and others. The cancer segment is expected to hold the major market share during the forecast period. This is primarily driven by the growing global cancer burden and the strong clinical success of bispecific antibodies in targeting tumor cells and activating immune responses.

The market is divided into four categories based on Distribution Channel: drug stores, retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies sector is expected to hold the major market share. This is because bispecific antibodies are primarily used in complex conditions like cancer and autoimmune diseases, which require specialized administration, monitoring, and inpatient care.

Bispecific Antibodies Market- Geographical Insights

The North America region is expected to hold the major market share in the global bispecific antibodies market during the forecast period, driven by advanced healthcare infrastructure, strong R&D investments, and early regulatory approvals by agencies like the U.S. FDA.

On the other hand, the Asia-Pacific region is projected to grow at the fastest rate, owing to rising cancer prevalence, increasing clinical trial activity, expanding healthcare access, and growing biopharmaceutical investments in countries such as China, India, and South Korea.

Bispecific Antibodies Market- Competitive Landscape:

Growing demand for targeted immunotherapies is intensifying competition, pushing companies to adopt strategies focused on innovation, clinical development, and regulatory approvals. Firms are investing heavily in R&D to enhance bispecific antibody formats, improve safety profiles, and increase efficacy in cancer and autoimmune treatments. Strategic collaborations, licensing deals, and expansion into emerging markets are also key approaches. Additionally, players are leveraging advanced platforms and proprietary technologies to accelerate pipeline progress and secure long-term competitive advantages in a rapidly evolving therapeutic landscape.

Recent Developments:

In March 2025, SanyouBio launched 73 bispecific antibody reference products covering approved and clinical-stage drugs, aiming to support drug development and address challenges by enabling dual-target binding to overcome limitations like resistance seen in single-target therapies.

In April 2025, Invenra Inc. announced the launch of its B-Body Express(TM) Antibody Expression service, allowing biotech and pharma companies rapid access to high-purity, validated bispecific antibodies from partner sequences, accelerating preclinical research with speed and advanced technology.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BISPECIFIC ANTIBODIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amgen
Genentech
Akeso, Inc.
Taisho Pharmaceutical
Janssen
Immunocore
Adimab, Innovent Biologics, Inc.
AstraZeneca
Affimed GmbH
Xencor
F. Hoffmann-La Roche Ltd.
Sanofi
Regeneron Pharmaceuticals Inc.
Pieris Pharmaceuticals, Inc.
Eli Lilly
Mereo BioPharma Group plc
Merus
MacroGenics, Inc.
Sobi, TG Therapeutics Inc.
Genmab A/S
Alteogen
Emergent BioSolutions Inc.
Novartis AG
Astellas Pharma Inc.
Celgene Corporation
Others

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

Immunoglobulin G
Non-Immunoglobulin G

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Inflammatory & Autoimmune Disorder
Cancer
Others

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Drug Stores
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Bispecific Antibodies Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Bispecific Antibodies Market Snippet by Drug Type
- 2.1.2. Bispecific Antibodies Market Snippet by Indication
- 2.1.3. Bispecific Antibodies Market Snippet by Distribution Channel
- 2.1.4. Bispecific Antibodies Market Snippet by Country
- 2.1.5. Bispecific Antibodies Market Snippet by Region
2.2. Competitive Insights

3. Bispecific Antibodies Key Market Trends

3.1. Bispecific Antibodies Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Bispecific Antibodies Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Bispecific Antibodies Market Opportunities
3.4. Bispecific Antibodies Market Future Trends

4. Bispecific Antibodies Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Bispecific Antibodies Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Bispecific Antibodies Market Landscape

6.1. Bispecific Antibodies Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Bispecific Antibodies Market - By Drug Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
- 7.1.2. Immunoglobulin G
- 7.1.3. Non-immunoglobulin G

8. Bispecific Antibodies Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 8.1.2. Inflammatory & Autoimmune Disorder
- 8.1.3. Cancer
- 8.1.4. Others

9. Bispecific Antibodies Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 9.1.2. Drug Stores
- 9.1.3. Retail Pharmacies
- 9.1.4. Hospital Pharmacies
- 9.1.5. Online Pharmacies

10. Bispecific Antibodies Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Bispecific Antibodies Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Bispecific Antibodies Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Bispecific Antibodies Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Bispecific Antibodies Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Bispecific Antibodies Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bispecific Antibodies Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Amgen
- 11.2.2. Genentech
- 11.2.3. Akeso, Inc.
- 11.2.4. Taisho Pharmaceutical
- 11.2.5. Janssen
- 11.2.6. Immunocore
- 11.2.7. Adimab, Innovent Biologics, Inc.
- 11.2.8. AstraZeneca
- 11.2.9. Affimed GmbH
- 11.2.10. Xencor
- 11.2.11. F. Hoffmann-La Roche Ltd.
- 11.2.12. Sanofi
- 11.2.13. Regeneron Pharmaceuticals Inc.
- 11.2.14. Pieris Pharmaceuticals, Inc.
- 11.2.15. Eli Lilly
- 11.2.16. Mereo BioPharma Group plc
- 11.2.17. Merus
- 11.2.18. MacroGenics, Inc.
- 11.2.19. Sobi, TG Therapeutics Inc.
- 11.2.20. Genmab A/S
- 11.2.21. Alteogen
- 11.2.22. Emergent BioSolutions Inc.
- 11.2.23. Novartis AG
- 11.2.24. Astellas Pharma Inc.
- 11.2.25. Celgene Corporation
- 11.2.26. Others

12. 360 Degree AnalystView

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us